S&P 500   4,010.99 (+0.20%)
DOW   32,562.61 (+0.01%)
QQQ   311.63 (+0.42%)
AAPL   160.16 (+0.55%)
MSFT   277.38 (+1.31%)
META   204.97 (+1.39%)
GOOGL   105.36 (+0.42%)
AMZN   100.75 (+0.14%)
TSLA   197.36 (-0.11%)
NVDA   270.85 (+3.38%)
NIO   9.33 (+0.65%)
BABA   84.29 (+0.70%)
AMD   99.46 (+3.68%)
T   18.57 (+0.16%)
F   11.78 (+0.51%)
MU   59.19 (+0.96%)
CGC   1.95 (-1.02%)
GE   91.63 (-0.60%)
DIS   96.74 (+0.21%)
AMC   4.56 (+3.40%)
PFE   40.35 (-0.76%)
PYPL   76.04 (-0.89%)
NFLX   302.10 (-1.21%)
S&P 500   4,010.99 (+0.20%)
DOW   32,562.61 (+0.01%)
QQQ   311.63 (+0.42%)
AAPL   160.16 (+0.55%)
MSFT   277.38 (+1.31%)
META   204.97 (+1.39%)
GOOGL   105.36 (+0.42%)
AMZN   100.75 (+0.14%)
TSLA   197.36 (-0.11%)
NVDA   270.85 (+3.38%)
NIO   9.33 (+0.65%)
BABA   84.29 (+0.70%)
AMD   99.46 (+3.68%)
T   18.57 (+0.16%)
F   11.78 (+0.51%)
MU   59.19 (+0.96%)
CGC   1.95 (-1.02%)
GE   91.63 (-0.60%)
DIS   96.74 (+0.21%)
AMC   4.56 (+3.40%)
PFE   40.35 (-0.76%)
PYPL   76.04 (-0.89%)
NFLX   302.10 (-1.21%)
S&P 500   4,010.99 (+0.20%)
DOW   32,562.61 (+0.01%)
QQQ   311.63 (+0.42%)
AAPL   160.16 (+0.55%)
MSFT   277.38 (+1.31%)
META   204.97 (+1.39%)
GOOGL   105.36 (+0.42%)
AMZN   100.75 (+0.14%)
TSLA   197.36 (-0.11%)
NVDA   270.85 (+3.38%)
NIO   9.33 (+0.65%)
BABA   84.29 (+0.70%)
AMD   99.46 (+3.68%)
T   18.57 (+0.16%)
F   11.78 (+0.51%)
MU   59.19 (+0.96%)
CGC   1.95 (-1.02%)
GE   91.63 (-0.60%)
DIS   96.74 (+0.21%)
AMC   4.56 (+3.40%)
PFE   40.35 (-0.76%)
PYPL   76.04 (-0.89%)
NFLX   302.10 (-1.21%)
S&P 500   4,010.99 (+0.20%)
DOW   32,562.61 (+0.01%)
QQQ   311.63 (+0.42%)
AAPL   160.16 (+0.55%)
MSFT   277.38 (+1.31%)
META   204.97 (+1.39%)
GOOGL   105.36 (+0.42%)
AMZN   100.75 (+0.14%)
TSLA   197.36 (-0.11%)
NVDA   270.85 (+3.38%)
NIO   9.33 (+0.65%)
BABA   84.29 (+0.70%)
AMD   99.46 (+3.68%)
T   18.57 (+0.16%)
F   11.78 (+0.51%)
MU   59.19 (+0.96%)
CGC   1.95 (-1.02%)
GE   91.63 (-0.60%)
DIS   96.74 (+0.21%)
AMC   4.56 (+3.40%)
PFE   40.35 (-0.76%)
PYPL   76.04 (-0.89%)
NFLX   302.10 (-1.21%)
NASDAQ:VERU

Veru - VERU Stock Forecast, Price & News

$1.42
-0.17 (-10.69%)
(As of 03/22/2023 02:09 PM ET)
Add
Compare
Today's Range
$1.36
$1.58
50-Day Range
$1.59
$6.41
52-Week Range
$1.36
$24.55
Volume
3.71 million shs
Average Volume
2.55 million shs
Market Capitalization
$114.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.33

Veru MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,895.3% Upside
$28.33 Price Target
Short Interest
Bearish
22.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of Veru in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.28) to ($0.78) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

414th out of 983 stocks

Pharmaceutical Preparations Industry

196th out of 478 stocks


VERU stock logo

About Veru (NASDAQ:VERU) Stock

Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm's breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects, and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and fin

Receive VERU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

VERU Stock News Headlines

Oppenheimer Cuts Veru (NASDAQ:VERU) Price Target to $9.00
Stock Market Update
This stock is taking America by storm. Find out why it's trending right now.
Why Is Veru (VERU) Stock Down 37% Today?
Stock Market Update
This stock is taking America by storm. Find out why it's trending right now.
Veru Inc. (NASDAQ:VERU) Q1 2023 Earnings Call Transcript
Is There any Hope for Veru Stock?
Veru Inc. (NASDAQ:VERU) Q4 2022 Earnings Call Transcript
Veru Full Year 2022 Earnings: Misses Expectations
Veru Inc. (VERU) Reports Q4 Loss, Lags Revenue Estimates
Is Veru a Buy?
See More Headlines
Receive VERU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

VERU Company Calendar

Last Earnings
12/02/2021
Today
3/22/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Personal Products
Sector
Medical
Current Symbol
NASDAQ:VERU
CUSIP
31446210
Employees
252
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$28.33
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+1,682.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-83,780,000.00
Net Margins
-412.01%
Pretax Margin
-411.82%

Debt

Sales & Book Value

Annual Sales
$39.35 million
Book Value
$1.01 per share

Miscellaneous

Free Float
61,380,000
Market Cap
$128.25 million
Optionable
Optionable
Beta
-0.15

Key Executives

  • Mitchell Shuster Steiner
    Chairman, President & Chief Executive Officer
  • Michele Greco
    Chief Financial & Administrative Officer
  • Robert H. Getzenberg
    Executive Vice President-Medical Affairs
  • Domingo Rodriguez
    Executive Vice President-Clinical Operations
  • K. Gary Barnette
    Chief Scientific Officer













VERU Stock - Frequently Asked Questions

Should I buy or sell Veru stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VERU shares.
View VERU analyst ratings
or view top-rated stocks.

What is Veru's stock price forecast for 2023?

5 Wall Street research analysts have issued 12-month price targets for Veru's shares. Their VERU share price forecasts range from $9.00 to $55.00. On average, they predict the company's stock price to reach $28.33 in the next year. This suggests a possible upside of 1,682.0% from the stock's current price.
View analysts price targets for VERU
or view top-rated stocks among Wall Street analysts.

How have VERU shares performed in 2023?

Veru's stock was trading at $5.28 at the beginning of 2023. Since then, VERU stock has decreased by 69.9% and is now trading at $1.59.
View the best growth stocks for 2023 here
.

When is Veru's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our VERU earnings forecast
.

How were Veru's earnings last quarter?

Veru Inc. (NASDAQ:VERU) posted its quarterly earnings data on Thursday, December, 2nd. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.04. The firm had revenue of $15.65 million for the quarter, compared to analyst estimates of $18.26 million. Veru had a negative trailing twelve-month return on equity of 119.37% and a negative net margin of 412.01%. During the same period in the prior year, the business posted ($0.01) earnings per share.

What ETFs hold Veru's stock?

ETFs with the largest weight of Veru (NASDAQ:VERU) stock in their portfolio include Fidelity MSCI Consumer Staples Index ETF (FSTA), Vanguard Consumer Staples ETF (VDC) and Carbon Collective Climate Solutions U.S. Equity ETF (CCSO) and

What other stocks do shareholders of Veru own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Kadmon (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), Organigram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

Who are Veru's major shareholders?

Veru's stock is owned by many different institutional and retail investors. Top institutional investors include Morgan Stanley (9.05%), Geode Capital Management LLC (1.37%), Millennium Management LLC (0.76%), Susquehanna International Group LLP (0.00%), Charles Schwab Investment Management Inc. (0.52%) and Boxer Capital LLC (0.43%). Insiders that own company stock include Harry Fisch, K Gary Barnette, Lucy Lu, Mario Eisenberger, Michele Greco and Mitchell Shuster Steiner.
View institutional ownership trends
.

How do I buy shares of Veru?

Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veru's stock price today?

One share of VERU stock can currently be purchased for approximately $1.59.

How much money does Veru make?

Veru (NASDAQ:VERU) has a market capitalization of $128.25 million and generates $39.35 million in revenue each year. The company earns $-83,780,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.

How many employees does Veru have?

The company employs 252 workers across the globe.

How can I contact Veru?

Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The official website for the company is www.veruhealthcare.com. The company can be reached via phone at (305) 509-6897, via email at veruinvestor@verupharma.com, or via fax at 312-595-9122.

This page (NASDAQ:VERU) was last updated on 3/22/2023 by MarketBeat.com Staff